2-Hydroxyestradiol slows progression of experimental polycystic kidney disease

Sharon Anderson, Terry T. Oyama, Jessie N. Lindsley, William E. Schutzer, Douglas R. Beard, Vincent H. Gattone, Radko Komers

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Male gender is a risk factor for progression of polycystic kidney disease (PKD). 17β-Estradiol (E2) protects experimentally, but clinical use is limited by adverse effects. Novel E2 metabolites provide many benefits of E2 without stimulating the estrogen receptor, and thus may be safer. We hypothesized that E2 metabolites are protective in a model of PKD. Studies were performed in male control Han:SPRD rats, and in cystic males treated with orchiectomy, 2-methoxyestradiol, 2-hydroxyestradiol (2-OHE), or vehicle, from age 3 to 12 wk. Cystic rats exhibited renal functional impairment (~50% decrease in glomerular filtration and renal plasma flow rates, P <0.05) and substantial cyst development (20.5 ± 2.0% of cortex area). 2-OHE was the most effective in limiting cysts (6.0 ± 0.7% of cortex area, P <0.05 vs. vehicle-treated cystic rats) and preserving function, in association with suppression of proliferation, apoptosis, and angiogenesis markers. Downregulation of p21 expression and increased expression of Akt, the mammalian target of rapamycin (mTOR), and some of its downstream effectors were significantly reversed by 2-OHE. Thus, 2-OHE limits disease progression in a cystic rodent model. Mechanisms include reduced renal cell proliferation, apoptosis, and angiogenesis. These effects may be mediated, at least in part, by preservation of p21 and suppression of Akt and mTOR. Estradiol metabolites may represent a novel, safe intervention to slow progression of PKD.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume302
Issue number5
DOIs
StatePublished - Mar 2012

Fingerprint

Polycystic Kidney Diseases
Sirolimus
Cysts
Estradiol
Apoptosis
Renal Plasma Flow
Kidney
Orchiectomy
Estrogen Receptors
Disease Progression
Rodentia
Down-Regulation
Cell Proliferation
2-methoxyestradiol
2-hydroxyestradiol

Keywords

  • Estrogen
  • Gender
  • Hydroxyestradiol p21
  • Hypoxia-inducible factor-1α
  • Mammalian target of rapamycin 2

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. / Anderson, Sharon; Oyama, Terry T.; Lindsley, Jessie N.; Schutzer, William E.; Beard, Douglas R.; Gattone, Vincent H.; Komers, Radko.

In: American Journal of Physiology - Renal Physiology, Vol. 302, No. 5, 03.2012.

Research output: Contribution to journalArticle

Anderson, Sharon ; Oyama, Terry T. ; Lindsley, Jessie N. ; Schutzer, William E. ; Beard, Douglas R. ; Gattone, Vincent H. ; Komers, Radko. / 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. In: American Journal of Physiology - Renal Physiology. 2012 ; Vol. 302, No. 5.
@article{4d8030cc5721469983ff0792c49521d0,
title = "2-Hydroxyestradiol slows progression of experimental polycystic kidney disease",
abstract = "Male gender is a risk factor for progression of polycystic kidney disease (PKD). 17β-Estradiol (E2) protects experimentally, but clinical use is limited by adverse effects. Novel E2 metabolites provide many benefits of E2 without stimulating the estrogen receptor, and thus may be safer. We hypothesized that E2 metabolites are protective in a model of PKD. Studies were performed in male control Han:SPRD rats, and in cystic males treated with orchiectomy, 2-methoxyestradiol, 2-hydroxyestradiol (2-OHE), or vehicle, from age 3 to 12 wk. Cystic rats exhibited renal functional impairment (~50{\%} decrease in glomerular filtration and renal plasma flow rates, P <0.05) and substantial cyst development (20.5 ± 2.0{\%} of cortex area). 2-OHE was the most effective in limiting cysts (6.0 ± 0.7{\%} of cortex area, P <0.05 vs. vehicle-treated cystic rats) and preserving function, in association with suppression of proliferation, apoptosis, and angiogenesis markers. Downregulation of p21 expression and increased expression of Akt, the mammalian target of rapamycin (mTOR), and some of its downstream effectors were significantly reversed by 2-OHE. Thus, 2-OHE limits disease progression in a cystic rodent model. Mechanisms include reduced renal cell proliferation, apoptosis, and angiogenesis. These effects may be mediated, at least in part, by preservation of p21 and suppression of Akt and mTOR. Estradiol metabolites may represent a novel, safe intervention to slow progression of PKD.",
keywords = "Estrogen, Gender, Hydroxyestradiol p21, Hypoxia-inducible factor-1α, Mammalian target of rapamycin 2",
author = "Sharon Anderson and Oyama, {Terry T.} and Lindsley, {Jessie N.} and Schutzer, {William E.} and Beard, {Douglas R.} and Gattone, {Vincent H.} and Radko Komers",
year = "2012",
month = "3",
doi = "10.1152/ajprenal.00265.2011",
language = "English (US)",
volume = "302",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease

AU - Anderson, Sharon

AU - Oyama, Terry T.

AU - Lindsley, Jessie N.

AU - Schutzer, William E.

AU - Beard, Douglas R.

AU - Gattone, Vincent H.

AU - Komers, Radko

PY - 2012/3

Y1 - 2012/3

N2 - Male gender is a risk factor for progression of polycystic kidney disease (PKD). 17β-Estradiol (E2) protects experimentally, but clinical use is limited by adverse effects. Novel E2 metabolites provide many benefits of E2 without stimulating the estrogen receptor, and thus may be safer. We hypothesized that E2 metabolites are protective in a model of PKD. Studies were performed in male control Han:SPRD rats, and in cystic males treated with orchiectomy, 2-methoxyestradiol, 2-hydroxyestradiol (2-OHE), or vehicle, from age 3 to 12 wk. Cystic rats exhibited renal functional impairment (~50% decrease in glomerular filtration and renal plasma flow rates, P <0.05) and substantial cyst development (20.5 ± 2.0% of cortex area). 2-OHE was the most effective in limiting cysts (6.0 ± 0.7% of cortex area, P <0.05 vs. vehicle-treated cystic rats) and preserving function, in association with suppression of proliferation, apoptosis, and angiogenesis markers. Downregulation of p21 expression and increased expression of Akt, the mammalian target of rapamycin (mTOR), and some of its downstream effectors were significantly reversed by 2-OHE. Thus, 2-OHE limits disease progression in a cystic rodent model. Mechanisms include reduced renal cell proliferation, apoptosis, and angiogenesis. These effects may be mediated, at least in part, by preservation of p21 and suppression of Akt and mTOR. Estradiol metabolites may represent a novel, safe intervention to slow progression of PKD.

AB - Male gender is a risk factor for progression of polycystic kidney disease (PKD). 17β-Estradiol (E2) protects experimentally, but clinical use is limited by adverse effects. Novel E2 metabolites provide many benefits of E2 without stimulating the estrogen receptor, and thus may be safer. We hypothesized that E2 metabolites are protective in a model of PKD. Studies were performed in male control Han:SPRD rats, and in cystic males treated with orchiectomy, 2-methoxyestradiol, 2-hydroxyestradiol (2-OHE), or vehicle, from age 3 to 12 wk. Cystic rats exhibited renal functional impairment (~50% decrease in glomerular filtration and renal plasma flow rates, P <0.05) and substantial cyst development (20.5 ± 2.0% of cortex area). 2-OHE was the most effective in limiting cysts (6.0 ± 0.7% of cortex area, P <0.05 vs. vehicle-treated cystic rats) and preserving function, in association with suppression of proliferation, apoptosis, and angiogenesis markers. Downregulation of p21 expression and increased expression of Akt, the mammalian target of rapamycin (mTOR), and some of its downstream effectors were significantly reversed by 2-OHE. Thus, 2-OHE limits disease progression in a cystic rodent model. Mechanisms include reduced renal cell proliferation, apoptosis, and angiogenesis. These effects may be mediated, at least in part, by preservation of p21 and suppression of Akt and mTOR. Estradiol metabolites may represent a novel, safe intervention to slow progression of PKD.

KW - Estrogen

KW - Gender

KW - Hydroxyestradiol p21

KW - Hypoxia-inducible factor-1α

KW - Mammalian target of rapamycin 2

UR - http://www.scopus.com/inward/record.url?scp=84857699451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857699451&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00265.2011

DO - 10.1152/ajprenal.00265.2011

M3 - Article

VL - 302

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5

ER -